CmlI is an N-oxygenase in the biosynthesis of chloramphenicol

Haige Lu a,1, Emmanuel Chanco b,1, Huimin Zhao a,b,*

a Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801, USA
b Department of Chemistry, University of Illinois at Urbana-Champaign, USA

A R T I C L E   I N F O

Article history:
Received 1 March 2012
Received in revised form 22 May 2012
Accepted 8 June 2012
Available online 19 June 2012

Keywords:
Chloramphenicol biosynthesis
Arylamine oxygenation
N-Oxygenation
Di-iron oxygenase

A B S T R A C T

The N-oxygenation of an amine group is one of the steps in the biosynthesis of the antibiotic chloramphenicol. The non-heme di-iron enzyme CmlI was identified as the enzyme catalyzing this reaction through bioinformatics studies and reconstitution of enzymatic activity. In vitro reconstitution was achieved using phenazine methosulfate and NADH as electron mediators, while in vivo activity was demonstrated in Escherichia coli using two substrates. Kinetic analysis showed a biphasic behavior of the enzyme. Oxidized hydroxylamine and nitroso compounds in the reaction were detected both in vitro and in vivo based on LC-MS. The active site metal was confirmed to be iron based on a ferrozine assay. These findings provide new insights into the biosynthesis of chloramphenicol and could lead to further development of CmlI as a useful biocatalyst.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

Aromatic nitro groups are relatively rare functional groups in natural products, but are found in diverse types of important antibiotics, such as chloramphenicol, pyrrolnitrin, aureothin, spectinomycin, azomycin, and rufomycin.1,2 The biosynthesis of aromatic nitro groups in natural products is poorly understood, and in particular the enzymes involved in catalyzing the formation of aromatic nitro groups are not well characterized. To date, only two N-oxygenases, PrnD3–5 and Aurf5–10 that are involved in the biosynthesis of pyrrolnitrin and aureothin, respectively, have been extensively characterized.

Chloramphenicol is a potent broad-spectrum antibacterial antibiotic produced by Streptomyces venezuelae and certain other actinomycetes.11 Because of its medical importance and unusual chemical structure (i.e., aromatic nitro group and dichloroacetamide moiety), the biosynthesis of chloramphenicol has been extensively investigated for more than four decades, mostly by Vining et al.11–15 The gene cluster for chloramphenicol biosynthesis has been identified and cloned, with expression in a heterologous host; however, the cluster was not fully characterized.14,16 In particular, the enzyme that catalyzes the formation of a nitro group in chloramphenicol remains unclear. Vining et al. proposed the final step of chloramphenicol biosynthesis to be the arylamine oxidation, based on feeding experiments with isotopically labeled compound 1.12 However, no biochemical or genetic evidence has been provided to support this hypothesis. Thomas et al. suggested that the arylamine intermediate might be oxidized by CmlI while the substrate is still bound to CmlI, a non-ribosomal peptide synthase.17 This is not without precedent; Lipscomb et al. recently characterized CmlA, which hydroxylates the L-α-amino-phenylalanine as it is still attached to CmlP.18 To shed light into this issue, we sought to use a variety of methods, such as bioinformatics, DNA cloning, and both in vitro and in vivo reconstitution of the enzyme to investigate the functional role of CmlI in chloramphenicol biosynthesis.

2. Results and discussion

Bioinformatic analysis indicated that CmlI shares ~34% amino acid sequence identity with Aurf. More importantly, like Aurf, two copies of the EX28–37DEXXH motifs are present in this protein. This motif is also conserved in several other di-iron oxygenases.7,10 Based on these results, we hypothesized that CmlI is a non-heme di-iron N-oxygenase. Subsequently, cmlI from the genomic DNA of S. venezuelae (NRRL ISP-5230) was cloned into pET26 vector with a His6-tag. DNA sequencing data suggested that there were a few errors in the previously reported sequence of cmlI. As a result, the total number of amino acids in our CmlI is 339 rather than the previously reported 338.14 The former number should be correct because the more recently sequenced genome of S. venezuelae ATCC 10712 also gives 339 amino acids for CmlI. This inevitably changes the translated sequence to a small degree, albeit it does not affect the conserved EX28–37DEXXH motifs (Fig. S1).

To study the activity in vitro, CmlI with an N-terminal His6-tag was over-expressed in Escherichia coli and further purified by affinity chromatography to be >95% pure (Fig. S2). Upon
concentration, the enzyme appeared light yellow in solution, suggesting the existence of metals or other cofactors.

The initial synthesis of substrate 1 (1R,2R)-(-)-2-(N-dichloroacetyl)-amino-1-(4-aminophenyl)-1,3-propanediol (Scheme 1, termed NH₂-Cam hereafter) following the reported catalytic hydrogenation procedure only resulted in de-chlorination of chloramphenicol. The synthesis was finally achieved by canonical acylation of a NH₂-Cam precursor with dichloroacetyl chloride (Supplementary data).

In the initial enzymatic assay, no conversion of NH₂-Cam was observed when mixed with purified Cmll. Inspired by our previous studies on AurF, we envisioned that the in vitro oxidation of NH₂-Cam by Cmll might require proper electron mediators. These mediators serve to replace the native enzymatic electron transfer systems such as ferredoxins. Three such compounds, namely phenazine methosulfate (PMS), phenazine ethosulfate (PES), and flavin mononucleotide (FMN), were tested in the presence of NH₂-Cam (A), while the nitro side product showed up with a retention time very close to or overlapping with chloramphenicol in all HPLC conditions tested (C). Intermediates were confirmed in negative mode LC–MS by the characteristic CI isotope pattern and detection of the correct parent ions (Fig. S4).

The oxidative steps in converting arylamine to arylnitro compounds have been discussed for AurF and PrnD, where aryl-amine was first oxidized to the hydroxylamines and nitroso compounds. Our effort to detect these intermediates in the reaction mixture of Cmll with NH₂-Cam enabled us to identify these compounds. As shown in Fig. 1, the hydroxylamine intermediate (B) elutes before the NH₂-Cam (A), while the nitroso side product showed up with a retention time very close to or overlapping with chloramphenicol in all HPLC conditions tested (C).

In vivo reconstitution of Cmll was also attempted. Addition of compound NH₂-Cam to E. coli expressing cmlI gave larger depletion of the substrate compared to controls, and appearance of peaks corresponding to the hydroxylamine, nitroso, and nitro compounds (Fig. S6). This was confirmed by detection of the product on HPLC, and detection of the correct masses on LC–MS for the intermediates. Similarly, feeding of p-aminobenzoic acid (5) showed some conversion of the substrate to the hydroxylamine, but the production of the nitro compound was not conclusively detected. The conversion of 1-4-aminophenylalanine (6), an intermediate in chloramphenicol biosynthesis, could not be determined, as the substrate was consumed at similar rates in both the sample and control, and the nitro product was not detected. The activity of Cmll on free substrates 1 and 5 suggests, but does not prove, that the N-oxidation occurs while the native substrate is not tethered to the native NRPS Cmll. It has been noted that the AurF can be reconstituted in the heterologous host due to a ribonucleotide reductase-like electron transfer pathway, and Cmll likely works by a similar mechanism by using reduced ferredoxins as a source for electrons. This is supported by the strict conservation of residues involved in electron transfer for Cmll and AurF (Fig. S1).

Fig. 1. HPLC trace of Cmll-catalyzed chloramphenicol formation in vitro at 285 nm. (A) Starting material NH₂-Cam (1); (B) hydroxylamine intermediate (2); (C) nitroso compound (3) and final product chloramphenicol (4).
However residues involved in ferredoxin binding are not strictly conserved. As CmII is also able to turn over the much smaller substrate 5, the presence of a keto or a hydroxyl group at the benzylc position may be sufficient for recognition as a substrate for at least the initial oxidation. This is similar to what has been found for AudF, but as CmII can accept much larger substrates, it may be more amenable for engineering as an N-oxidation catalyst.8 It remains to be seen what other factors determine the substrate specificity of CmII.

Various metals have been found in oxygenases to mediate substrate oxidation.25–29 Although it is clear now that AudF, a homolog of CmII, is a non-heme di-iron N-oxidase, we cannot rule out the existence of other metals in CmII. To address this issue, we analyzed by ICP-MS the metal contents in CmII purified from cells cultivated in Luria–Bertani medium. Only Fe was found to be significantly present. To rule out the possible involvement of Mn in catalysis, which was once suggested for AudF,10 the ratio of Mn and Fe in CmII were further assessed for purified cells cultivated in either Luria–Bertani medium or M9 minimal medium with equal amounts of Fe and Mn added. The concentration of Fe in the protein was much higher than that of Mn, by about 17-fold in both cases. The Fe/CmII ratio ranged from 1.2 to 1.4 (Table 1). When we used the iron-specific ferrozine assay,23 the Fe to CmII ratio was found to be 2:1 (Table 1). Taken together, our data seem to suggest that CmII, just like AudF, is also a di-iron oxygenase.

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>Fe/Mn ratio (ICP)</th>
<th>Fe/CmII ratio (ICP)</th>
<th>Fe/CmII ratio (ferrozine)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CmII from M9</td>
<td>17</td>
<td>1.4</td>
<td>2.2</td>
</tr>
<tr>
<td>CmII from LB</td>
<td>17</td>
<td>1.2</td>
<td>1.8</td>
</tr>
</tbody>
</table>

3. Conclusions

We have reported the first biochemical characterization of the N-oxidase CmII and confirmed its role in chloramphenicol biosynthesis. Reconstitution of the enzyme activity was achieved in vitro via addition of chemical reductants and in vivo in *E. coli*. Furthermore, our data show that CmII, just like AudF, is a non-heme di-iron oxygenase. These findings have opened the door for further mechanistic and structural studies of this type of oxygenases and biocatalyst development using protein engineering tools.

4. Materials and methods

4.1. Bacteria strains and culture conditions

The wild-type strain of *S. venezuelae* ATCC 10712 was obtained from the American Type Culture Collection (ATCC, Manassas, VA). *S. venezuelae* and its derivatives were maintained on ISP2 agar medium and cultivated in YGM liquid medium (malt extract 5 g/L, yeast extract 2 g/L, glucose 2 g/L) at 28 °C with shaking at 250 rpm. Genomic DNA was isolated using the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI) using standard protocols.

4.2. Overexpression and purification of CmII

The cmlI gene was amplified by PCR from the genomic DNA of *S. venezuelae* (NRRL ISP-5230) and cloned into pET26 vectors (Novagen, Gibbstown, NJ) using a forward primer (5’-CAGTTCATATGCGGATTCAACACACGAGAATTGAATC-3’) and a reverse primer (5’-GCTAAGCTTCTCAGGCTGTTTCCACGTTGCTG-3’) between Ndel and HindIII sites (underlined sequences). The corresponding plasmid was transformed into *E. coli* BL21 (DE3) cells. Kanamycin (50 μg/mL) was used as a selection marker. For expression of *cmlI* in Luria–Bertani medium, cells were grown at 37 °C to OD600=0.6–0.8. Then protein expression was induced by 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and the cells were agitated at 250 rpm and 25 °C overnight. For expression of CmII in M9 medium, cells were grown in M9 medium at 37 °C to OD600=0.6–0.8. To the culture were added L-methionine (60 mg/L), L-leucine (50 mg/L), L-isoleucine (50 mg/L), L-valine (50 mg/L), L-lysine (100 mg/L), L-threonine (100 mg/L), L-phenylalanine (100 mg/L), (NH₄)₂Fe(SO₄)₁₂ (0.5 mM), and MnSO₄ (0.5 mM). Protein expression was induced by IPTG (0.1 mM), and cells were agitated at 250 rpm and 18 °C overnight. The cell lysate was prepared by passing cells resuspended in buffer (20 mM Tris-HCl, pH=7.5, 100 mM NaCl, 1 mM β-mercaptoethanol, 5% glycerol) twice through French Press®. N-His₆-tagged CmII was purified off Co-column to over 95% purity. Purified CmII was then dialyzed against storage buffer (50 mM HEPES, 10% glycerol). Protein was quantified using the Bradford Quickstart Reagent (Bio-Rad, Hercules, CA) using bovine serum albumin as a standard.

4.3. In vitro and in vivo assays

In vitro assays of CmII were performed on a 600 μL scale. The final reaction mixture contained CmII (5–20 μM) substrate NH₂–Cam (250 μM), PMS (100 μM), NADH (1 mM), and HEPES (20 mM, pH=7.5). Reactions were performed at room temperature (23–25 °C) and were started by addition of NADH to the reaction mixture. Reaction was quenched by trifluoroacetic acid (final concentration 0.8% v/v) and centrifuged. For in vivo reconstitution of CmII, cells were grown similar to cells used for purification, except that Terrific Broth medium was used instead of Luria–Bertani broth. Cells were pelleted by centrifugation, washed twice in assay buffer (25 mM MOPS, 8 g/L NaCl, 1 g/L KCl, 2 g/L glucose, pH 7.2), and resuspended to a final OD600 of 15 in a final volume of 50 mL. Substrate was added to a final concentration of 250 μM, and the reaction was followed for 3 h at 30 °C, taking time points every 30 min. As a control, cells containing only the vector were used, and subjected to the same analysis and time course.

4.4. LC–ESI-MS and ESI-MS/MS analysis of chloramphenicol

Samples were analyzed via reverse-phase liquid chromatography on an Agilent 1100 HPLC. The conditions were: Zorbax SB-C18 column, 3.0×150 mm (Agilent); mobile phase A: 25 mM ammonium acetate (pH=6.8), mobile phase B: methanol; flow rate 0.5 mL/min, HPLC program as shown in Table S1. Compound 1 was quantitated at 237 nm, while 4 was quantitated at 285 nm by comparison with standards with known concentrations. An alternative HPLC method was used for in vivo assays, where buffer A (1% acetic acid) and buffer B (methanol) both contained 2 mM sodium 1-heptanesulfonic acid to improve peak shape and separation for the alternate substrates used. For mass spectroscopy work, an Agilent 1100 series LC/MSD XCT plus-ion-trap mass spectrometer was utilized. Identical mobile phases and columns were used as previously indicated, with a flow rate of 300 μL/min and the HPLC program shown below. The column effluent was directed to Agilent XCT ion-trap MSD mass spectrometer, which was operated in the negative ion mode to detect parent ions of each of the reaction intermediates. The system was operated using a drying temperature of 350 °C, a nebulizer pressure of 35 psi, a drying gas flow of 8.5 L/min, and a capillary voltage of 4500 V.

4.5. Ferrozyme assay

The procedure was largely adapted from published protocol with slight modification.29 Briefly, 50 μL protein (20–200 μM
range) was mixed with an equal volume of reducing reagent and incubated at room temperature for 5 min, followed by addition of 50 μL 12% trichloroacetic acid. After centrifugation, 100 μL supernatant was transferred to 40 μL 10% ammonium acetate buffer, followed by addition of 10 μL ferroin reagent. The mixture was incubated for 10 min at room temperature, and the absorbance was subsequently measured at 562 nm. Mohr’s salt was used to prepare the standard solutions, and molar extinction coefficient at 562 nm was 28,000 M−1 cm−1. The reducing reagent consisted of 48 μL A [ascorbic acid (4 mM), H2SO4 (0.1 M)] and 2 μL B [phenazine methosulfate (10 mM)]. The ferroin reagent was composed of ferroin reagent. The mixture was incubated at room temperature for 5 min, followed by addition of 10% ammonium acetate buffer, 1 cm

References and notes